narcolepsy

View All

Sleep Aids Market
Sleep Aids Market: Examining Cutting-Edge Technologies and Major Breakthroughs

Sleep Aids Market: Examining Cutting-Edge Technologies and Scientific Breakthroughs Sleep can be burdensome when it disrupts daily routines, requires a significant time commitment, and is marred by sleep disorders or disturbances that affect overall well-being. In today's fast-paced world, where stress, anxiety,...

Find More

sleep-disorders-market-symptoms-risk-factors-types-and-treatment-options
Sleep Disorders: An Emerging Public Health Issue

Sleep is essential for the physical and mental health of the person. If a person didn’t get proper sleep, it might lead to many health complications. In recent time, due to various reasons such as busy work schedule, changes in sleep patterns, stress, environmental factors, certain medical conditions or medications...

Find More

Narcolepsy drug WAKIX
FDA approves Non-Controlled treatment for Excessive Daytime Sleepiness

The U.S. Food and Drug Administration has approved WAKIX (pitolisant) to treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy. The Narcolepsy therapy, developed by HARMONY therapeutics, is the first and the only treatment to get approval that is not labelled as a controlled substance by the US...

Find More

Narcolepsy
Narcolepsy now a confirmed Autoimmune Disorder

The concept of sleep as a passive movement of unconsciousness has long been ruled out. But this act of rejuvenation hasn't just been restricted to the phase of resting. Usually, sleepers undergo five stages of sleep consisting of both REM (Rapid Eye Movement) and N-REM (Non- Rapid Eye Movement), each lasting f...

Find More

Narcolepsy: Treatment options and market outlook

Narcolepsy is characterized by symptoms such as excessive daytime sleepiness, cataplexy (sudden loss of muscle control, often triggered by strong emotions) and fragmented sleep. Narcolepsy occurs throughout the world but occurrence rates vary among populations. Occurrence of Narcolepsy is estimated to be 1 in 2,000 ...

Find More